
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen is a clinical-stage biotechnology company that holds significant potential in the treatment of neuromuscular and neurologic diseases with its Enhanced Delivery Oligonucleotide platform. The completion of enrollment in the 10mg/kg multi-dose cohort in the FREEDOM2 study is a positive development and the upcoming 2H26 data readout is a key catalyst for the company. While there were concerns with the earlier 5mg/kg PGN-EDODM1 data, the observed increase in drug concentrations over time and the management's comments on the safety profile are reassuring.
Bears say
PepGen is facing several challenges, such as the need for additional external funding to advance their development platform, safety concerns with two subjects experiencing transient albuminuria, and delays in their development plan due to the need for more investigation. Additionally, the company's valuation discount rate has increased to 40% due to safety being a key driver for advancement. This lowered target price to $5 from $9 reflects the uncertainty surrounding their pipeline and their need to resolve a clinical hold with the FDA.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares